ArticleFrontiers in pharmacology2025
Wubi Shanyao pills ameliorate diet-induced postmenopausal osteoporosis in mice by enhancing calcium absorption.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Wubi Shanyao Pills (WSP) is a traditional Chinese botanical formulation known for its gastrointestinal and renal benefits, yet its pharmacological effects on postmenopausal osteoporosis (PMOP) are not well elucidated. This study aimed to evaluate the therapeutic potential of WSP in a diet-induced PMOP model and to investigate its underlying mechanisms related to calcium absorption. Methods: A PMOP-like model was established in perimenopausal mice using a low-calcium, high-phosphorus diet. The mice were treated daily with WSP (0.375, 0.75, or 1.5 g/kg) or alendronate (ALN) (0.14 g/kg). After 17 weeks of treatment, bone microstructure was assessed via small animal CT, along with evaluation of systemic physiological parameters and hematological profiles. Histopathological examinations of the ileum, kidney, and femur were conducted using hematoxylin-eosin (H&E) staining, Alcian blue-periodic acid-Schiff (AB-PAS), and Masson staining. Serum calcium and phosphorus levels were measured by enzyme-linked immunosorbent assay (ELISA). The expression levels of calcium absorption-related proteins were analyzed using immunohistochemistry (IHC), immunofluorescence (IF), Western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR). Results: WSP exhibited notable pharmacological effects by improving bone mass/quality and serum calcium/phosphorus levels in diet-induced PMOP mice, mediated via upregulating key calcium transport proteins: transient receptor potential vanilloid 5 (TRPV5) and calcium-binding protein (CABP) in the kidney, transient receptor potential vanilloid 6 (TRPV6) and CABP in the ileum, and vitamin D receptor (VDR) in the femur; moreover, WSP reversed PMOP-associated anemia and facilitated tissue structural repair in the kidney, ileum, and femur. Conclusion: WSP modulates diet-induced PMOP pathology by promoting calcium absorption via the restoration of organ integrity and regulation of the TRPV5/TRPV6-CABP and VDR-mediated calcium metabolism pathways, thereby underlying its pharmacological effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.